SCHEMBL10054792

SCHEMBL10054792

Cc1ccc(NC(=O)c2ccc(C)c(C(F)(F)F)c2)cc1NC(=O)/C=C/c1cccnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 5/20 0.58
CSF1R P07333 3/20 0.58
KIT P10721 4/20 0.55
KDR P35968 4/20 0.55
PDGFRA P16234 3/20 0.55
NAMPT P43490 6/20 0.54
MEN1 O00255 1/20 0.54
GALR2 O43603 1/20 0.54
LMNA P02545 1/20 0.54
MAPT P10636 1/20 0.54
HPGD P15428 1/20 0.54
RECQL P46063 1/20 0.54
KMT2A Q03164 1/20 0.54
ABL1 P00519 3/20 0.53
HDAC1 Q13547 2/20 0.52
HDAC3 O15379 1/20 0.51
PDGFRB P09619 1/20 0.51
BCR P11274 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2679829 1.00 BRAF (0.58) BRAFCSF1RKITKDRPDGFRA
SCHEMBL2679206 0.96 CSF1R (0.57) BRAFCSF1RKITKDRPDGFRA
SCHEMBL10077755 0.96 CSF1R (0.57) BRAFCSF1RKITKDRPDGFRA
SCHEMBL2679311 0.95 CSF1R (0.54) BRAFCSF1RKITKDRPDGFRA
SCHEMBL10054803 0.95 CSF1R (0.54) BRAFCSF1RKITKDRPDGFRA
SCHEMBL2679138 0.92 KIT (0.54) BRAFCSF1RKITKDRPDGFRA
SCHEMBL10054807 0.92 KIT (0.54) BRAFCSF1RKITKDRPDGFRA
SCHEMBL2679244 0.91 CSF1R (0.54) BRAFCSF1RKITKDRPDGFRA
SCHEMBL10078752 0.91 CSF1R (0.54) BRAFCSF1RKITKDRPDGFRA
SCHEMBL10078410 0.90 BRAF (0.62) BRAFCSF1RKITKDRPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-8426446-B2 Acrylamide derivative and use thereof in manufacture of medicament BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) 2013-04-23 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120116075-A1 Acrylamide Derivative And Use Thereof In Manufacture Of Medicament ABL1, ABL2, BCR BRAF 21/4885CSF1R 2608/4885KIT 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.